BiotechTube
Circle Pharma

Circle Pharma

South San Francisco, United States· Est.
circlepharma.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $201M

Overview

Circle Pharma, founded in 2014, is a private biotech company pioneering the development of macrocyclic drugs for oncology. Its core asset is the MXMO™ discovery platform, which aims to systematically design and optimize macrocycles to inhibit challenging intracellular targets. The company is pre-clinical/pre-revenue, building a pipeline focused on transforming cancer treatment through improved selectivity and patient experience. Leadership includes CEO David J. Earp, who brings extensive experience in biotech IP, legal affairs, and corporate development.

Oncology

Technology Platform

Proprietary MXMO™ (Macrocycle X, Macrocycle Optimization) platform for the rational design and optimization of macrocyclic peptides to target intracellular 'undruggable' protein-protein interactions.

Funding History

3
Total raised:$201M
Series D$90M
Series B$66M
Series A$45M

Opportunities

The opportunity lies in successfully drugging high-value intracellular oncology targets currently considered 'undruggable,' addressing significant unmet medical needs.
The macrocycle modality also offers the potential for oral dosing and improved tolerability, which could differentiate its therapies in the competitive cancer market.

Risk Factors

Key risks include the technical challenge of consistently developing drug-like macrocycles, intense competition from other modalities targeting similar protein-protein interactions, and the substantial financial requirements of a pre-revenue biotech with a long development pathway.

Competitive Landscape

Circle Pharma competes with other biotechs focused on macrocycles and cyclic peptides (e.g., Bicycle Therapeutics, PeptiDream), as well as companies pursuing alternative 'undruggable' target modalities like molecular glues, PROTACs, and targeted protein degradation. Large pharma also have significant internal efforts in this space.

More companies in Small Molecule Drugs →More companies in United States →